ZAROXOLYN Tablets (metolazone tablets, USP) for oral administration contain 2 Â˝, 5, or 10 mg of metolazone, USP, a diuretic/saluretic/antihypertensive drug of the quinazoline class.
ZAROXOLYN is indicated for the treatment of salt and water retention including:
edema accompanying congestive heart failure;
edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function.
ZAROXOLYN is also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if MYKROX Tablets are to be substituted for ZAROXOLYN in the treatment of hypertension. See package circular for MYKROX Tablets (Celltech).
Published Studies Related to Zaroxolyn (Metolazone)
Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. [1997.03]
This study compared the incidence of cough with the angiotensin-converting enzyme (ACE) inhibitor lisinopril and the diuretic metolazone with angiotensin II receptor antagonist losartan in elderly hypertensive patients with previous histories of ACE inhibitor-induced cough... The specific, selective angiotensin II receptor antagonist losartan is associated with a decrease in the incidence of cough in patients with previous ACE inhibitor-induced cough.
Addition of metolazone to overcome tolerance to furosemide in infants with bronchopulmonary dysplasia. [1992.06]
A decreased response to the loop diuretic furosemide develops within a few doses in young infants. We tested the hypothesis that the use of the thiazide-like diuretic metolazone, in combination with furosemide, would inhibit water and electrolyte reabsorption and overcome pharmacologic tolerance to furosemide alone.
The evaluation of the diuretic action of parenteral formulations of metolazone. [2007.01]
BACKGROUND AND OBJECTIVES: This study was design to compare the diuretic and natriuretic effects of the 2 parenteral formulations of metolazone and the combination of these 2 formulations of metolazone with the parenteral administration of furosemide. Metolazone is an anthracrene acid derivate and manifests a dual diuretic effect on the proximal and distal tubule with a minimal kaluretic effect. It is currently only marketed in an orally administrable formulation, and this has limited its utility in critically ill patients. Metolazone given orally and furosemide given orally or parenterally are frequently administrated together when furosemide alone is clinically inadequate at producing a desired diuresis... CONCLUSION: Combining metolazone and furosemide can cause an increase in urine volume and sodium excretion. Metolazone administrated parenterally in combination with the parenteral administration of furosemide appears to have an important clinical potential.
Beneficial effects of metolazone in a rat model of preeclampsia. [2006.09]
Preeclampsia is a disorder that continues to exact a significant toll with respect to maternal morbidity and mortality as well as fetal wastage...
Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. [2005.08]
CONCLUSION: The literature review and the observational study support the use of low-dose metolazone (< or =5 mg) on top of oral loop diuretics, as an effective and relatively safe treatment in contemporary outpatients with refractory HF.
Clinical Trials Related to Zaroxolyn (Metolazone)
Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan metolazone 5 mg
tablets to Celltech Zaroxolyn® 5 mg tablets following a single, oral 10 mg (2 x 5 mg) dose
administration under fasting conditions.
Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan metolazone 10 mg
tablets to Celltech Zaroxolyn® 10 mg tablets following a single, oral 10 mg (1 x 10 mg) dose
administration under fasting conditions.
Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan metolazone 2. 5 mg
tablets to Celltech Zaroxolyn® 2. 5 mg tablets following a single, oral 10 mg (4 x 2. 5 mg)
dose administration under fasting conditions.
Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis [Recruiting]
Patients who are on mechanical ventilation in an intensive care unit often require diursis
as part of their pre-extubation regimen. The drug of choice for diuresis has traditionally
been furosemide. However, this drug cause hypernatremia (a rise in serum sodium) in a
significant proportion of patients. Hypernatremia is traditionally treated by providing free
water supplementation to the patient. This strategy creates a vicious and unproductive cycle
of giving free water, and then diuresing it off. We propose a strategy for breaking this
cycle by using a second diuretic-- metolazone-- which has a tendency to rid the body of more
sodium, thereby minimizing hypernatremia.
Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure [Recruiting]
The purpose of this prospective, randomized, open-label study is to compare two diuretic
strategies in patients with acute decompensated heart failure (ADHF): the addition of an
oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to
transition from IVB to continuous infusion (CI) loop diuretic.
Reports of Suspected Zaroxolyn (Metolazone) Side Effects
Confusional State (4),
Cardiac Failure Congestive (3),
Heart Rate Decreased (3),
Renal Failure (3),
Micturition Disorder (3),
Gait Disturbance (3), more >>
Page last updated: 2007-05-03